Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NewAmsterdam Pharma Company N.V. Warrant (NAMSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: NAMSW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Year Target Price $
Year Target Price $
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.54% | Avg. Invested days 21 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.03 | 52 Weeks Range 5.45 - 16.75 | Updated Date 05/17/2025 |
52 Weeks Range 5.45 - 16.75 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2314.47% |
Management Effectiveness
Return on Assets (TTM) -18.15% | Return on Equity (TTM) -31.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 54899238 |
Shares Outstanding - | Shares Floating 54899238 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NewAmsterdam Pharma Company N.V. Warrant
Company Overview
History and Background
NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on the research and development of transformative therapies for cardio-metabolic diseases. The company was founded in 2019, focusing on developing obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, for major unmet needs in high-risk cardiovascular patients.
Core Business Areas
- Pharmaceutical Research and Development: Focuses on the research and development of novel therapies for cardio-metabolic diseases.
- Drug Commercialization: Aims to commercialize developed drugs such as obicetrapib upon regulatory approval.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical development and commercialization. The organizational structure includes departments for research, clinical development, regulatory affairs, and commercial planning.
Top Products and Market Share
Key Offerings
- Obicetrapib: Obicetrapib is NewAmsterdam Pharma's lead product candidate, a CETP inhibitor designed to lower LDL-C and reduce cardiovascular risk. The market share is not yet applicable as the drug is in late-stage development. Competitors include statins, PCSK9 inhibitors, and other emerging therapies targeting lipid metabolism.
Market Dynamics
Industry Overview
The pharmaceutical industry focusing on cardio-metabolic diseases is characterized by high unmet needs and significant market potential. It's driven by the increasing prevalence of cardiovascular diseases and diabetes worldwide.
Positioning
NewAmsterdam Pharma aims to become a key player in the cardio-metabolic disease therapeutics market by developing and commercializing obicetrapib, potentially offering a new treatment option for patients with high cardiovascular risk.
Total Addressable Market (TAM)
The total addressable market for lipid-lowering therapies is substantial, estimated to be in the tens of billions of dollars. NewAmsterdam Pharma is positioned to capture a portion of this market with obicetrapib, pending regulatory approval.
Upturn SWOT Analysis
Strengths
- Promising lead product candidate (obicetrapib)
- Experienced management team
- Focus on a large and growing market
Weaknesses
- Reliance on a single product candidate
- Dependence on successful clinical trials and regulatory approvals
- Competition from established players
Opportunities
- Potential to address unmet needs in cardio-metabolic diseases
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other therapies
- Patent disputes
Competitors and Market Share
Key Competitors
- AMGN
- REGN
- SNY
Competitive Landscape
NewAmsterdam Pharma faces competition from established pharmaceutical companies with existing lipid-lowering therapies. Its competitive advantage lies in obicetrapib's potential to offer a differentiated mechanism of action and improved clinical outcomes.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of obicetrapib through clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization efforts.
Recent Initiatives: Recent initiatives include the completion of Phase 3 trials for obicetrapib and preparations for regulatory submissions.
Summary
NewAmsterdam Pharma is a promising biotech company focused on developing novel therapies for cardio-metabolic diseases. Obicetrapib holds significant potential, but the company faces risks associated with clinical trials, regulatory approvals, and competition. Successful commercialization of obicetrapib could lead to substantial growth, but failure in late-stage trials could severely impact the company's prospects. Investors should closely monitor clinical trial results and regulatory developments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Clinical trial data
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data and market share estimates are subject to change. The company's future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewAmsterdam Pharma Company N.V. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-11-23 | CEO, President, Executive Board Member & Director Dr. Michael Harvey Davidson FACC, Facp., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 77 | |
Full time employees 77 | |||
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.